Humana AB (SE:HUM)
:HUM
Want to see SE:HUM full AI Analyst Report?
Top Page
Humana AB
(HUM)
Select Model
Select Model
Rating:58Neutral
Price Target:
kr50.00
▼(-0.79% Downside)
Action:ReiteratedDate:04/28/26
The score is held back primarily by weakening revenue and an above-average leverage profile, partially offset by strong free cash flow generation. Technicals are supportive with the stock trading above major moving averages and neutral-to-positive momentum indicators, while valuation is reasonable (mid-teens P/E with a ~2% yield).
Positive Factors
Free cash flow generation
Consistent and improving free cash flow is a durable strength: positive FCF across periods and strong TTM growth support capital allocation, fund working capital and maintenance capex, and provide a buffer versus cyclical pressures in public-sector reimbursed care services.
Negative Factors
Revenue decline
Meaningful and persistent revenue declines undermine scale economics and put pressure on utilization, contract renewals and pricing negotiations with public payors. Over months this can erode margins, slow deleveraging and constrain reinvestment in services or staffing.
Read all positive and negative factors
Positive Factors
Negative Factors
Free cash flow generation
Consistent and improving free cash flow is a durable strength: positive FCF across periods and strong TTM growth support capital allocation, fund working capital and maintenance capex, and provide a buffer versus cyclical pressures in public-sector reimbursed care services.
Read all positive factors
Humana AB (HUM) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr2.51B
Dividend Yield2.01%
Average Volume (3M)120.62K
Price to Earnings (P/E)15.2
Beta (1Y)0.56
Revenue Growth-4.47%
EPS Growth6.10%
CountrySE
Employees11,127
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.01
Shares Outstanding51,826,057
10 Day Avg. Volume123,370
30 Day Avg. Volume120,620
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.81
Price to Sales (P/S)0.25
P/FCF Ratio3.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.64
Revenue Forecast (FY)kr10.21B
Humana AB Business Overview & Revenue Model
Company Description
Humana AB (publ) provides individual and family care services for children and adults in Sweden, Finland, Norway, and Denmark. It operates through five segments: Individual & Family, Personal Assistance, Elderly Care, Finland, and Norway segments....
How the Company Makes Money
Humana AB makes money by delivering contracted care services and receiving reimbursement/fees—primarily funded by public-sector payors—based on the type and volume of care delivered. Key revenue streams typically include: (1) Personal assistance s...
Humana AB Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
46
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.96B | 10.01B | 10.29B | 9.65B | 9.20B | 8.19B |
| Gross Profit | 3.26B | 831.00M | 896.00M | 757.00M | 9.14B | 8.13B |
| EBITDA | 1.05B | 1.11B | 1.05B | 908.00M | 901.00M | 892.00M |
| Net Income | 199.00M | 237.00M | 144.00M | 176.00M | 210.00M | 276.00M |
Balance Sheet | ||||||
| Total Assets | 9.46B | 9.39B | 10.63B | 10.03B | 9.81B | 9.00B |
| Cash, Cash Equivalents and Short-Term Investments | 254.00M | 366.00M | 583.00M | 675.00M | 690.00M | 695.00M |
| Total Debt | 4.39B | 6.72B | 5.15B | 5.41B | 5.40B | 4.92B |
| Total Liabilities | 6.17B | 6.14B | 7.33B | 7.10B | 7.07B | 6.45B |
| Stockholders Equity | 3.16B | 3.12B | 3.16B | 2.89B | 2.74B | 2.55B |
Cash Flow | ||||||
| Free Cash Flow | 660.00M | 666.00M | 570.00M | 451.00M | 442.00M | 582.00M |
| Operating Cash Flow | 721.00M | 770.00M | 869.00M | 621.00M | 633.00M | 689.00M |
| Investing Cash Flow | -90.00M | 172.00M | -532.00M | -151.00M | -246.00M | -260.00M |
| Financing Cash Flow | -1.05B | -1.13B | -434.00M | -457.00M | -424.00M | -521.00M |
Humana AB Technical Analysis
Positive
50.40
Price Trends
45.28
Positive
47.01
Positive
43.99
Positive
Market Momentum
0.46
Positive
53.35
Neutral
24.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:HUM, the sentiment is Positive. The current price of 50.4 is above the 20-day moving average (MA) of 46.58, above the 50-day MA of 45.28, and above the 200-day MA of 43.99, indicating a bullish trend. The MACD of 0.46 indicates Positive momentum. The RSI at 53.35 is Neutral, neither overbought nor oversold. The STOCH value of 24.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:HUM.
Humana AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | kr2.13B | 23.52 | ― | ― | 10.34% | 2.50% | |
65 Neutral | kr16.04B | 15.03 | ― | 1.47% | 0.06% | 89.86% | |
63 Neutral | kr11.12B | 17.78 | 12.96% | 1.56% | 12.99% | 9.19% | |
61 Neutral | kr1.64B | 143.44 | ― | ― | ― | ― | |
58 Neutral | kr2.51B | 15.17 | 7.53% | 2.01% | -4.47% | 6.10% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | kr1.22B | -8.76 | -35.03% | ― | ― | 46.92% |
* Healthcare Sector Average
SE:HUM
Humana AB
48.50
9.92
25.73%
SE:ATT
Attendo AB
106.40
42.45
66.37%
SE:AMBEA
Ambea AB
140.10
27.92
24.89%
SE:XSPRAY
Xspray Pharma AB
26.65
-6.35
-19.24%
SE:STIL
Stille AB
237.50
49.50
26.33%
SE:CARA
Carasent AB
23.90
-0.41
-1.69%
Humana AB Corporate Events
Humana lifts Swedish margins but profits and cash flow weaken in Q1
Apr 24, 2026
Humana reported a modest improvement in profitability in Sweden, with margins rising from 4.3% to 4.6%, supported by the early effects of an efficiency programme. The company also strengthened its position in social and elderly care through the co...
Humana Reschedules 2026 AGM After Technical Error in Meeting Notice
Apr 24, 2026
Humana AB has withdrawn its previously announced notice convening the Annual General Meeting scheduled for May 7, 2026, after discovering a technical error that prevented shareholders from accessing the notice as required under the Swedish Compani...
Humana Calls 2026 AGM, Expands Options for Shareholder Voting
Apr 24, 2026
Humana AB’s board has called its 2026 Annual General Meeting, to be held on June 1 in Stockholm, giving shareholders the opportunity to participate either in person, by proxy or through a structured postal voting system. The company has set ...
Humana AB Sets June 1, 2026 AGM With Expanded Voting Options
Apr 24, 2026
Humana AB has called its annual general meeting for June 1, 2026, in Stockholm, giving shareholders the opportunity to participate either in person, by proxy, or through postal voting in line with its articles of association and Swedish company la...
Humana Sets April 24 Date to Present First-Quarter 2026 Results
Apr 14, 2026
Humana will publish its interim report for the first quarter of 2026 at 08:00 CET on 24 April, followed by a combined telephone conference and webcast at 09:00 CET where CEO and President Nathalie Boulas Nilsson and CFO Christoffer Herou will pres...
Humana sets May 7, 2026 AGM with expanded postal voting options
Mar 31, 2026
Humana AB has called its annual general meeting for May 7, 2026, in Stockholm, setting out how shareholders can participate either in person, by proxy or through postal voting. The notice details registration deadlines, procedures for nominee̴...
Humana Once Again Crowned Sweden’s Most Sustainable Healthcare Provider
Mar 12, 2026
Humana has been named Sweden’s most sustainable healthcare provider for the fourth time by the Sustainable Brand Index, underscoring its position as an industry leader that embeds sustainability into its business model. The recognition refle...
Humana to Double LSS Daily Activity Services with Homsan Acquisition
Mar 10, 2026
Humana has agreed to acquire Homsan AB, a Stockholm-region provider of daily activities under LSS, more than doubling Humana’s daily activity services and significantly expanding its local footprint. Homsan runs 13 units with around 200 part...
Humana Boosts Profitability, Cuts Debt and Lifts Dividend Despite Lower 2025 Revenue
Feb 6, 2026
Humana AB reported weaker fourth-quarter 2025 revenue of SEK 2,483 million, down 8% year-on-year, with organic growth at -1.9% and adjusted operating profit falling to SEK 87 million, while full-year net revenue slipped 3% but operating profit ros...
Humana AB Launches Share Buyback to Bolster Capital Structure and Acquisition Flexibility
Feb 6, 2026
Humana AB’s board has decided to repurchase up to 1,000,000 of the company’s own shares under a mandate from the 2025 annual general meeting, aiming to strengthen its capital structure and increase strategic flexibility for potential f...
Humana Completes Acquisition of Norwegian Care Provider Familiehjelpgruppen
Feb 2, 2026
Humana AB has completed the acquisition of Norwegian care provider Familiehjelpgruppen AS, following approval from the national Competition Authority. The deal significantly expands Humana’s preventive care and support services for children ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.